The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | Where do new drugs fit into the treatment landscape of multiple myeloma?
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ talks about new drugs being used for the treatment of multiple myeloma (MM), and where they fit in the current treatment landscape. He discusses how drugs like elotuzumab can be used in the early relapsed setting, whilst daratumumab is more suitable for 3rd line therapy. He also talks about anti-CD38 therapies being used much earlier, perhaps even as front-line therapy or in combination with other drugs.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
